
SEPN
Healthcare · Biotechnology · $2.03B market cap
$42.60+0.74 (+1.8%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +28.2% over 90 days · 30-day revisions 2 up, 1 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 9, 2026 | After the close | -0.55 | -0.57 | -3.6% |
| Aug 10, 2026 | After the close | -0.48 | -0.29 | +39.6% |
| May 11, 2026 | After the close | -0.44 | -0.19 | +56.8% |
| Mar 26, 2026 | Time not confirmed | -0.72 | -0.24 | +66.7% |
| Nov 10, 2025 | Before the open | 0.79 | -0.10 | -112.7% |
| Aug 11, 2025 | After the close | 0.93 | -0.56 | -160.2% |
| May 15, 2025 | After the close | -0.38 | -0.49 | -28.9% |
| Mar 27, 2025 | Time not confirmed | -0.69 | -0.64 | +6.8% |
| Nov 20, 2024 | After the close | -0.94 | -8.40 | -793.6% |
| Aug 28, 2024 | Time not confirmed | — | -12.76 | — |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric…